Not for publication, distribution or release, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Japan, South Africa or any other jurisdiction in which it would be unlawful to do so.
International legal practice Osborne Clarke has advised Bone Therapeutics SA on its successful fund raising of EUR 8.5 million in gross proceeds through a EUR 5 million private placement of new shares via an accelerated bookbuild offering, and a EUR 3.5 million non-dilutive subordinated bond placement.
Bone Therapeutics is a leading biotech company listed on Euronext Brussels and Paris focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases. Bone Therapeutics’ core technology is based on its off-the-shelf allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells.
The team of Osborne Clarke in Belgium was led by David Haex and Hadrien Chef and included Tonya Aelbrecht, Violette Keppenne, Laurent Donnay de Casteau and Olivier Lambillon. The Belgian team was also supported by Sophie Jouniaux (Tax, OC France).
Osborne Clarke combines sector knowledge and a global reach to support clients in the pharmaceutical, biotech and medtech sectors.
This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.
Corporate communications and press contacts
Connect with one of our experts
